Q1 2019 13F Holders as of 31 Mar 2019
-
Type / Class
-
Equity / SHS
-
Total 13F shares
-
7,416,360
-
Share change
-
-226,787
-
Total reported value
-
$60,589,170
-
Price per share
-
$8.17
-
Number of holders
-
34
-
Value change
-
-$1,338,068
-
Number of buys
-
13
-
Number of sells
-
22
Institutional Holders of GALMED PHARMACEUTICALS LTD - SHS (GLMD) as of Q1 2019
As of 31 Mar 2019,
GALMED PHARMACEUTICALS LTD - SHS (GLMD) was held by
34 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
7,416,360 shares.
The largest 10 holders included
BVF INC/IL, 683 Capital Management, LLC, Vivo Capital, LLC, Nantahala Capital Management, LLC, Ibex Investors LLC, MEITAV DASH INVESTMENTS LTD, BAKER BROS. ADVISORS LP, Knoll Capital Management, LP, FIRST MIDWEST BANK TRUST DIVISION, and P.A.W. CAPITAL CORP.
This page lists
34
institutional shareholders reporting positions in this security
for the Q1 2019 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.